-
Clinical Trials & Development1 week agoSTAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more
The latest pharma news from the Pharmalot campus via the Pharmalittle newsletter
-
Clinical Trials & Development1 week agoAutoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
-
Clinical Trials & Development1 week agoUltragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing strategic review
The success of apazunersen in a Phase 3 trial for Angelman syndrome was a key driver of Ultragenyx’s value, according to William Blair, and the asset’s...
-
Clinical Trials & Development2 weeks agoSTAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial
Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.
-
Clinical Trials & Development2 weeks agoAffordability and Access: Why patient perspectives matter
“Context around patient-identified affordability and access challenges is really critical,” began Karin Hoelzer, DVM, PhD, Senior Director, Patient Advocacy during the Biotechnology Innovation Organization’s […] The...
-
Clinical Trials & Development2 weeks agoAutoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
Wall Street analysts believe that a more cautious approach to manufacturing, study enrollment and side effect management could help developers avoid future safety hazards.
-
Clinical Trials & Development2 weeks agoNovartis’ Rhapsido cuts MS progression in Phase 3 trial, teeing up Roche battle
Novartis is planning to file for remibrutinib’s expanded approval in relapsing multiple sclerosis by next year, putting it just behind Roche's own BTK inhibitor fenebrutinib.
-
Clinical Trials & Development2 weeks agoUltragenyx Announces Phase 3 Aspire Results for Apazunersen (GTX-102) in Angelman Syndrome
NOVATO, Calif., September 2, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced results from the Phase 3 Aspire study for apazunersen (GTX-102) in...
-
Clinical Trials & Development2 weeks ago
Teva Announces Positive Topline Results from Phase 2a Study of TEV ‘408 in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
TEL AVIV, Israel, September 2, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced positive topline results from an ongoing Phase...
-
Clinical Trials & Development2 weeks agoTYK2 inhibitor miss pushes Alumis toward precision strategy for lupus
BIOCENTURY | PRODUCT DEVELOPMENTTYK2 INHIBITOR MISS PUSHES ALUMIS TOWARD PRECISION STRATEGY FOR LUPUSSubgroup signal suggests IFN enrichment could rescue envudeucitinib’s Phase II all-comers miss — a strategy...
Carbon Dots Emerge as a Powerful Weapon Against Superbugs and Biofilms
Your Zip Code May Shape Your Breast Cancer Tumor’s Genetics and Your Survival Odds
Azithromycin Resistance in Gonorrhea Shifts Genetic Ground, Challenging Molecular Surveillance
Scientists turn pig semen extract into eye drops that kill cancer in mice
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
